amgen on valuation, that's higher.t is what that -- >> you stick with this trade, regeneron, even on the pullback. >> regeneron's a great company. i get it. but the stock has been ballistic. the valuation is a little bit absurd. i'd rather own amgen here still. >>> all right. time for pops and drops. big movers of the day. got a drop for nvidia down 2%. guy. >> downgraded it. $18 price target. i don't think it gets there. it held 21 there. you stay long this name against 21 bucks. >> pop for amazon up 1%. tim. >> the alibaba of the united states actually doing very well here. but what's doing well here is it's holding on to a valuation in a stock that lost all investor sentiment holding that 430 level where it spiked up to. i think you can be neutral on this stock at these levels. >> pop for caesars up 6%. >> $6 stock here. lots of option activity in it. but this is a stock that has gotten destroyed this year. it's almost an option itself at $6. if i'm going to play the casino space i'd much rather be in wynn than in c

it will be interesting to hear how the panel discusses the amgen competitor drug tomorrow. that advisory committee meeting starting tomorrow morning. but again, regeneron coming in with a positive vote but a potentially narrow patient population, melissa. >> meg tirrell, thanks for that. guy adami, how do you trade this? >> first vote, the 14-3 vote was expected p. as meg said the second vote was narrower than anticipated. the stock was halted regeneron but just on valuation if you want to get back at brass tacks i'd rather own amgen with 14, 15 times earnings with potential up side of their drug than regeneron which has been on a monster run trading closer to 40 times. i think there's more down side risk in regeneron, there's still up side in amgen. >> we've got a market flash. change in the s&p. >> tobacco-related. we know that reynolds american is buying lorillard. lorillard already a member of the s&p, is now no longer going to be there. s&p, dow jones indices says the new company is qorvo. the ticker qrvo. it will replace lorillard in the s&p 500 effective after the cl

the share price of amgen biotech company got approval for its cholesterol drug.ot bad. 1.5%. >> amgen has a similar drug in the biotech space for cholesterol. this advisory panel says people who have super high levels of cholesterol go ahead and use this drug. that is what they recommend to the fda for approval. this could be a big boost for amgen. regeneron also has a similar drug with restrictions. amgen getting a better nod from the fda advisory panel. it's all about the cholesterol. you've got to watch it. >> there's no way he has high cholesterol. have you seen what he eats? stuart: two slices of whole wheat toast no butter. one or two grapefruit, nonfat yogurt with various, cnn. that is my diet. two cups of coffee black. i want to get back to jc. you are like one energy stocks. explain so. >> i really think the perfect storm could be brewing here for a company well known out there chesapeake energy. we are starting to see momentum. it is not just oil. a ton of exposure in the natural gas space with smart money if you love really loading up natural gas right

. >> food and drug administration panel had backed amgen's highly revolutionary cholesterodrug. they say the benefits outweigh the risks but that it should only be used in patients at high risk of cardiovascar disease. yesterday, a panel voted a similar drug shoue ap but again, f veryse >>> two major cities want people to eat better and they are proposing new rules toet you to do san francisco taking aim at sugary drinks, while new york city is setting ghts salt. sarah eisen has more. >> sweet or salty? both are coming undr fi in manhattan, officials proposed new rules today requiring chain restaurants to include a warning label on menus for items high in salt. dishes with more than the daily limit of 2300 milligrams of sodium. also, san franisthe ir citto require health warnings on ads fosuga drinks the mane pr ru sconer, he wants to educate consumeut the health risks of drinking soda. >> sugary drinks are almost half of all sugar consumed in the american diet. one 12 ounce can of soda has ten teaspoons of sugar and these drinks are absolutely fuel ingling the elope ii di thate

a similar therapy by amgen goes before the advisory panel tomorrow.here's hope behind the new drugs. >> lipitor was once the top-selling drug in the world. it's part of a class of medicines called statens which have the ability to drastically lower cholesterol, but statens don't work for everyone and heart disease thought to be connected to levels of bad cholesterol known as ldl is still the leading cause of deaths worldwide. >> there's still a need in the n treatment of cholesterol because a good proportion of patients still don't reach goal with the fat therapy or the other available therapies. >> phil nato estimates 15% of patients can't tolerate statens because of side effects like muscle pain and he says 20% don't get cholesterol levels low enough to keep them from being at high risk of heart attack or stroke. that's where a new class of drugs came in. developed by regeneron partnered with sanifee they are partnered by outside advisers. >> so far they haven't seen a lot of side effects. >> moreover they've shown to reduce cholesterol levels by 40

question tomorrow whether amgen will also be halted. >> does one follow the other? goes through tonight, it's likely to go through tomorrow? >> that's the thought. they are very similar. they are different what it they are dosed. people think they are looking similar to each other now. >> nice to see you meg. >>> just about half hour to go in this session. that's where you'll see a pick up in volume. feels like we are sitting on that fence. what are you watching? >> interest rates and yields on the ten year moving our markets other than that individual areas, continue to watch the financials. the conference going on you guys are covering has been moving those stocks. goldman sachs having a health care conference. those are the two areas we are focused on in the trading floor. aside from that it's the yields. >> speaking of yields how about that jolt we got earlier this morning? >> that's a direct impact on what you are seeing in the ten-year yield. that's having an impact. we have to stop saying we are tightening and look at it as normalizing. job openings and labor

a panel of the fda has endorsed the use of the new amgen drug rapatha for some patients with high cholesterol. it's part of a new class of biotech drugs that lower cholesterol more effectively than the common statin medications. >>> a chance encounter gave two bay area sweethearts a second chance at love. it's a love connection 50 years in the making. a half century. 76-year-old darryl cameron of saint helena thought he had lost the love of his life when his wife died. a couple of years later his pals suggested meet up with his old girlfriend. two had dated for two years in the '60s but broke up because she didn't want to get married. but when they reunited 50 years later they got engaged within a few months. >> i know what it's like to be happily married and really love somebody. she passed away. it was just -- i lost a lot. >> darryl and his fiancee are moving to tennessee to start a new life, a new love and a new adventure. probably a little cheap there are. >> they are so cute together. >> good for them. >>> 4:57. bay area police call it disgraceful a war memorial spray-painted and now a

amgen is moving higher with that cholesterol drug recommendation from the fda panel, and we continueon a bit under the ropes as they had more questions with their recommendation for approval. those cholesterol drugs are something that the health care industry is looking at. this could be another widely prescribed expensive band of drugs. back to you. >> bertha thank you very much. >>> let's head down to the bond pits after retail fell. interesting interestingly the dollar is stronger. >> absolutely. the way all the markets hook up at the hip is definitely in flux a lot lately. the notion of such a decent retail sales. it's decent. i would venture to say that the fundamentals right now are important, but as you see, we had a range of 249,8 to 242 in 10s so far today. up 1.2 data you can clearly see there was some roll tilt, but the established trend was pretty much her in place, a two-day chart reveals, gentlemen psychologically you always have 2 and a quarter, 250, 275, some psychological resistance but as you open the chart up we're comping to bakley the latter part of the month. th

jen --ft, apple, and amgen are all heavyweights within the nasdaq., if you look at the s&p and the sectors that are the tech heavy nasdaq is having its day as well, and it is the best performing of the three major averages. now it is up 1.3% and trading at that new record. pimm? pimm: thanks very much, that is julie hyman on the news from nasdaq. and more breaking news from attorney general loretta lynch. she says the shooting suspect from south carolina is in custody. nine people were killed in the shooting in charleston, s.c.. president obama will speak later on that situation and we will bring that to you live. is the father, he of the united states financial system and is about to get kicked off the $10 bill. we are going to talk to and alexander hamilton biographer of how this change -- biographer about this change. ♪ pimm: welcome back to the "bloomberg market day." i am pimm fox. the $10 bill may be getting a feminine they slip. treasury secretary jack lew says put on aman will be $10 bill and he is accepting suggestions. i spoke with the auth

they really are neck and neck from amgen and regeneron.s widely expected they'll get approved over the summer. >> why do statins become less effective in people and could these drugs end up replace statins? >> some people get side effects with statins. some just doesn't get to goal with lowering their ldl, bad cholesterol enough. that changes the game when you have these pills as opposed to injections. we don't have data yet in hour these drugs do in preventing those events. that could broaden the patient population. peak sales estimates for these drugs, $5 billion a year but it could initially be slower uptake. it's better for inspirion. >> dr. j. biotech, where do you go? >> regenorron. another all-time high today. stock is up from $25 to $520. you wanted performance that's apple-like performance, this company has done it. >> albert edwards will break his silence in his first televised interview in years. a top analyst will explain why an even bigger deal could be on the horizon. stay tuned. that is mobile, it is you. real madrid have ab

amgen is waiting the fda's nod for a similar drug. >>> still to come, the one important thing more thanght-year-olds were willing to stand in line to wait for, and it had nothing to do with justin bieber. of course not! they were eight! can you spot the difference? no? you can't see that? alright, let's take a look. the one on the right just used 1% less fuel than the one on the left. now, to an airline, a 1% difference could save enough fuel to power hundreds of flights around the world. hey, look at that. pyramids. so you see, two things that are exactly the same have never been more different. ge software. get connected. get insights. get optimized. every auto insurance policy has a number. but not every insurance company understands the life behind it. ♪ those who have served our nation have earned the very best service in return. ♪ usaa. we know what it means to serve. get an auto insurance quote and see why 92% of our members plan to stay for life. it's a highly thercontagious disease.here. it can be especially serious- even fatal to infants. unfortunately, many people who spread

sure there is a competitive product head by amgen. let's not miss the forest for the trees here.est selling statin of all time lipitor, but they didn't come up with the alternative. america merck invented the class. it's little r are egene are ron in the lead. you know the biotech rally while getting too hot at certain times does overall make sense. how about gilead? remember when it did nothing for months as people looked at whether they would squeak the margins because it was charging the too much for the hepatitis c cure? i emphasize cure. do you notice in the last month and a half gilead went from 100 to 119 in part because the hep-c is too god food for companies not to offer and it is stock piling for a transformative acquisition or should i say another one? in reel al ti the reason why they are in a position for a big deal, why it has the cash is it was willing to fork up $11 billion for a money losing company called pharmaset which the scientists gauged had a winner in the help tights c platform. gilead paid 89% premium for pharmaset. they knew there was no thinking about

but 11-4 positive vote for amgen. kelly, back to you. >> meg thank you so much.so welcome steve grasso off the floor. what are you trading? >> interesting when you were talking about the outperformance with the finals. take a look at energy. energy has been so beaten down. now you start to see that whiplash back. a lot of guys thought it got ahead of itself. started to factor in $85 barrel of oil. now it's coming back now. people that had to really sort of dig in and see what the valuations were as long as you're above $60 in oil, i think it's not all clear, but guys are really starting to dabble. >> and it's interesting, i just came back from a financial services conference last week. and pretty much every strategist picked that oil was going to end up the year, like $70 to $75 a barrel. so certainly, the sentiment is yes, it's moving on up. >> it's definitely the equilibrium is $60 a barrel. and it's all weighted toward the dollar. what's the dollar doing? if you can tell what the next move is in the dollar that solves a lot of big questions with the market. >>

amgen got approval today, too from the panel. therefore they said no one will want what experian has. overreaction. but experian didn't move up too much. i toll you to be careful of it. it may not be done going down but i want you to buy regeneron. i'm not here to undermine today's positive action but understand we aren't out of the woods yet. we're in a calm grassland. at least for today. on "mad money" today, one share of the stock will cost you 235 bucks, but don't let you scare you away from the massive bottom. then in flute player left for dead but up over 10% in the last month on a legit turnaround. and here's a hint -- you'd be nuts not to buy it. plus, game-changing app that puts your doctor in the palm of your hand. stick with cramer! >> don't miss a second of "mad money." follow @jimcramer on twitter. have a question? tweet cramer #madtweets. send jim an e-mail to madmoney@cnbc.com. or give us a call at 1-800-743-cnbc. miss something? head to madmoney.cnbc.com. >>> after one of the best days for stocks in ainges ss in a

biotech does well, names like selgene, has been up about seven out of the past ten years and amgen hasaverage 11% over the same time period. health care providers and services also get a boost. it's a likely scenario that again as expected this year with the industry group leading the sector year to date amid the merger speculation. humana up more than 5.5%. cigna, averaging a 7% increase. from june through august. and health care strong performance usually continues into fall. so according to sam stovall at s&p capital, the from may to october, the s&p has returned an average 1.6% gain. health care has logged a 5% increase. one reason he suggests, exposure to the sector over this time period. scott, back over to you. >> morgan, thanks so much. so stef, now we know what kensho says, what does the portfolio manager core of tiaa cref think about the space? >> we like it. a lot of our pms are overweight. i'm overweight the health care sector. there are a lot of pockets in health care that are attractivea activity. the hmos saying you're going from five guys to three. that's what you are a

amgen regeneron, have not opened pending news from the fda. let's get to the tsa story. were on the terror watch list. elizabeth macdonald is here what is the story? liz: the story is surprising from the inspector general of homeland security. you do not submit a social security number to get a credential or airport clearance. 87,000 workers do not have social security numbers who work at airports across the country for the tsa. 75,000 don't even have-- don't have passport i.d. numbers not submitted them because it's not required. what kind of security clearance is tsa doing for workers. go ahead, stuart. stuart: the tsa says we don't have the information on these people who are working as vendors, for example. >> they don't require it. they don't require the numbers. in other words, they're handing out credentials without getting social security numbers to an i ply. stuart: they handed out credentials for people. you're waiting in line to go through the metal detector and somebody comes up with a badge and says here i go and off i go and walk through. those people have

. >>> good cholesterol news for amgen's drug. >> 14-1, in favor -- i'm sorry, i'm just terrible here.4 was the fda vote on this one. judge. wanted to give you the right number. this is popped above the 00-day moving average. just shy of the 50-day. i think it pushes well over 160 on this move. >>> and how about box, breaking news, exclusively by our own david faber, fox, rupert murdoch preparing to step down as ceo of 21' century fox and handing the reins to his sons. >> however gave me box and fox. i thank you, i'm a huge dr. seuss fan. both of these are names that i would sell. fox has no trend. good news doesn't move it up. bad news doesn't seem it 0 move it down. it's pretty cheap stock but it's been cheap for a while. not a buyer. >> coming up, the three $3 trillion trade that could be a nightmare for your portfolio. plus here's a look at the s&p sector heat map right now. off the best levels of the day. >> where's the heat map? there it is. the s&p sup by 4.33. we're back after this. when a rewards card is designed to sync with your life, it gets talked about... ♪ ♪ so you can l

big cap names because they're far more solid they trade literally like pharma names these days, the amgenselgene with the big buyback they announced. those names still -- >> with those little guys it's a lot of trading. >> a lot of fun. >> let's get to another big after hours mover but this one's in the opposite direction and it's oracle. the earnings call is still under way. in fact, it's now well under way. cnbc's josh lipton has been monitoring that call. what more have we heard, josh? >> well, mandy, on that oracle conference call executives trying to sound a note of confidence. here's what mark herd, oracle's co-ceo, had to say. take a listen. >> we're now growing faster than both salesforce and workday. and we expect revenue growth next year could be as high in fast pass as 60%. we're doing what you very rarely ever see happen in our industry. we are getting bigger. and our growth rate is expanding. we will be the world's largest enterprise cloud company. >> ellison saying oracle's cloud business will grow faster than workday. things are good for oracle in the cloud, he said. mandy,

you get gilead, you get amgen-u get biogen, regeneron, get all of them and you get inside lailted toin sxent to these binary events and that's what the retail audience should focus on. >> coming up on the program oracle earnings on deck. the tech giant is supposed to report after the bell tomorrow and some traders are betting big that the stock will move higher. why? perhaps they had history on their side. and we'll explain that when we come back. you probably know xerox as the company that's all about printing. but did you know we also support hospitals using electronic health records for more than 30 million patients? or that our software helps over 20 million smartphone users remotely configure e-mail every month? or how about processing nearly $5 billion in electronic toll payments a year? in fact, today's xerox is working in surprising ways to help companies simplify the way work gets done and life gets lived. with xerox, you're ready for real business. and life gets lived. ♪ hp instant ink can save you up to 50% on ink delivered to your door, so print all you want and never run

so right now these are drugs being made by regeneron and amgen. they're very similar drugs and they're having beviewed today and tomorrow. everyone expects these to get approved. the question is what patient population should they be approved for? we know they lower the bad cholesterol but they haven't showed what the out comes of that are. >> but there's hereditary people too. which is really the problem. one out of three people are on them right now. so still the cause and effect -- >> that's right. it is more accepted it will lead to a risk of cardiovascular ooecht events. people expect these drugs to be approved and we should see the outcome studies testing howell they do lowering the risk. >> leading cause of death among men and women. >> absolutely. the question here that's so interesting is because these are injected drugs how much are people going to want to take them? there's a slight difference between the drugs in that amgen offers one dose and you can take it either once every two weeks where you inject it once each time or once a mont

in addition amgen winning backing approval from an fda panel. the adviser group saying a cholesterol lowering drug from the company should be approved for some patients with dangerously high levels of the artery clogging substance. >> let's check on the markets this morning as we showed you it looks like the futures are higher again this morning despite the fact that the market was up so strongly yesterday. yesterday the dow was up by 263 points. that was a gain of 1.3%. the s&p up by 1.2% and those were the best days in a month. the nasdaq up by 1.25% and that was the best day in two weeks. take a look at the early trading in europe this morning. at least at this point it looks like green arrows there as well. the dax in germany up by .3%. even greece which we know has been active and all over the place this morning it's up by about 7%. putting it back above 815. check out what happened overnight in asia. the nikkei was also higher. up by 1.7%. the hang seng was higher as was the shanghai composite. oil prices yesterday settled at their highest

take amgen.ar says in addition to cost cuts if this big cap biotech has one of the best pipelines it had in a long time. analysts estimate this stock could gain 12% over the next 12 months. william blair likes another big cap name biogen. he thinks this could outperform thanks to four highly anticipated clinical trials. you can see here the implied up side for this stock, 16%. another one, small cap is nektar. this is a name with a lot of assets. it's often overlooked. analysts expect a 38% gain over the next year. novavax, results for four clinical trials expected next quarter. that could gain 23% over the next year. lastly, kite pharma. this is a name that maxim group rated as a buy yesterday. that could gain 31% over the next year based on consensus estimate. names to check out. >>> from biotech stocks to micro bios. >> earlier we were talking about johnson&johnson which is trying to mine trillions of microorganisms this live in and on our body that scientists discovered have serious implicati

. >> i'm not talking the amgens and the biogens, i'm talking about the 150 to 200 ipos brought publicy the investment banks over the last couple of years with no sales. >> gary, in a bubble, a bubble is a market overvaluation, it's not just a sector. maybe biotechs are overvalued. they have the huge run right now. we don't see that cab driver talking about day trading stocks like we do in 1999. or like we saw in 2008. neil: jonathan, give you pause, history is hindsight, 20/20, there was day trading and everybody making money within minutes. we don't see that to the extent we did back then, that's true. what about the other frenetic activity, not to the point which jonathan hoenig would step back? >> first of all, we're going to correct. trees don't go to the sky. i will be looking for two things, first of all, more audience, more investor participation week haven't seen people shuffling money in the stock market like previous bubbles, and more than anything, lower prices. when you see people buying on the way down that's when you should see it out. neil: take a chill pill, it's not h

fda advisory panel recommended the agency the full one approved amgen's cholesterol lowering drug, only used in patients though at high risk of cardiovascular disease and also they have to do more studies on long-term benefits and costs. same drug was run by regeneron which is moving lower again today. some investors worried the restrictions could limit the amount of money these companies could make. >>> solitaire surfing the web, how employees really waste time at work. >>> plus apple retail employees not happy with ceo tim cook over his security bag check policy. we'll explain. >>> plus -- >> today's powerhouse is home to qualcomm headquarters. it is ranked the seventh largest city in the u.s. and it is edged with 70 miles of beaches. can you name that city? ♪ ♪ ♪ at chase, we celebrate small businesses every day through programs like mission main street grants. last years' grant recipients are achieving amazing things. carving a name for myself and creating local jobs. creating more programs for these little bookworms. bringing a taste of louisiana to the world. at chase, we're proud

. >> i want to ask you about something that's different with your drug and amgen's. an extra question because they only offer one dose of your drug. you offer two doses of your drug. why is that better do you think? >> well our feeling was we wanted to develop a drug that would lower ldl cholesterol. but if it got too low meaning we don't know what that means and we haven't seen results from going very low, but we're getting to unchartered territory. we're seeing people who have familial are seeing lowering. and we felt that you should have flexibility in dosing. where if a doctor came down too low, he could come down to a lower dose. that was our strategy. we think it was a good strategy. and i think that if it gets aprooued that way, the doctors will like that. >> you were nice what you said about statins. but i would have said i get a huge market share with this. so what is your projection for market share for this? even if statins continue to be the first choice. >> it's not even if they should be the first choice. they should be the first choice. let's just be c

they have partnerships with amgen. and just announced with bluebird. the national cancer institute that shows what these therapies are able to do. they say they can work where other therapies just don't work anymore. you can see they're showing some of the cancers on the left. the before and after with the treatment of what happens to the cancers basically looking like they disappear. this is working on patients with those who have other options. >> thank you very much. come on over to the set. joining us right now is dr. ari beldigrun. thank you again for being here today. >> good to be here. >> so what's exciting about this is the amazing options that it gives you when it looks like there are no other options out there. this was just at nih, but now you're working at some hospitals around the country. >> that's correct. just about a month ago we had started a clinical trial across the united states where we are believing for the first time this treatment. it comes out from a center manufacturing place. the therapy is now becoming available under the

nicole: we're looking at amgen and cholesterol, no one wants high cholesterol, don't want the risk ofrt attack and stroke and everybody knows some of the popular names, lipitor and also crestor. it turns out these are injectables and different ways to prevent the cholesterol from getting into your body. it could be very costly it could cost $1,000 a month, $10 billion a year in sales, but so far they're doing well here moving this forward. and some people can't tolerate the other drugs, the statins, lipitor and crestor. stuart: i'm going to bring you the etf on cyber security a basket of stocks basically represented by that etf. it's up 20% this year. keith in seattle, you like this a lot, don't you, this particular etf? >> absolutely. if you're not investing in cyber security after the government hanking, the bank fraud preaches at target and retailers are' being naive. there's billions at stake. hack is easy way to play that because it's a basket of cyber security companies. stuart: assuming that the security companies can keep us secure, a nice assumption to make. everybody, we're